title: Synergistic induction of MCP-1 and -2 by IL-1beta and interferons in fibroblasts and epithelial cells.
abstract: Monocyte chemotactic protein (MCP)-1 and MCP-2, two closely related CC chemokines, are important mediators of monocyte and lymphocyte migration. These chemokines are secreted by various normal cell types, including fibroblasts, epithelial cells, and leukocytes, as well as by tumor cells. After stimulation with different cytokines and cytokine inducers the MCP-2 production levels are always lower than those of MCP-1. In human diploid fibroblasts cytokines differentially regulate chemokine induction, interleukin (IL)-1beta and interferon (IFN)-gamma being potent stimuli of MCP-1 and MCP-2, respectively. Co-stimulation of fibroblasts by 10 U/mL IL-1beta and 20 ng/mL IFN-gamma resulted in a synergistic induction of MCP-2, whereas the combined effect on MCP-1 and IL-6 production was rather additive. These findings were confirmed at the mRNA level by Northern blot analysis. In contrast, in human MG-63 fibroblastoid cells and HEp-2 epithelial cells, selected for their poor responsiveness to IL-1beta and IFN-gamma, MCP-2 as well as MCP-1 and IL-6 were synergistically induced, yielding protein levels that were increased 3- to 30-fold above the additive levels. When IFN-beta was used as a co-stimulant of IL-1beta, a similar synergistic induction of MCP-1 and MCP-2 was measured both at the protein and the mRNA level. It can be concluded that, when synergy occurred, the MCP-1 and MCP-2 expression levels reached a comparable maximum, indicative for an equal contribution of these chemokines in normal and pathological conditions.
authors.affiliation: Rega Institute for Medical Research, Laboratory of Molecular Immunology, University of Leuven, Belgium.
authors.forename: S
authors.initials: S
authors.lastname: Struyf
authors.forename: E
authors.initials: E
authors.lastname: Van Collie
authors.forename: L
authors.initials: L
authors.lastname: Paemen
authors.forename: W
authors.initials: W
authors.lastname: Put
authors.forename: J P
authors.initials: JP
authors.lastname: Lenaerts
authors.forename: P
authors.initials: P
authors.lastname: Proost
authors.forename: G
authors.initials: G
authors.lastname: Opdenakker
authors.forename: J
authors.initials: J
authors.lastname: Van Damme
mesh_terms: D002455:Cell Division / Q000187:drug effects; D002460:Cell Line; D018932:Chemokine CCL2 / Q000096:biosynthesis*; D054412:Chemokine CCL8; D004357:Drug Synergism; D004847:Epithelial Cells / Q000276:immunology; D005347:Fibroblasts / Q000276:immunology; D006801:Humans; D016899:Interferon-beta / Q000494:pharmacology*; D007371:Interferon-gamma / Q000494:pharmacology*; D007375:Interleukin-1 / Q000494:pharmacology*; D015850:Interleukin-6 / Q000494:pharmacology; D018945:Monocyte Chemoattractant Proteins / Q000096:biosynthesis*; D012333:RNA, Messenger / Q000096:biosynthesis; D011994:Recombinant Proteins / Q000494:pharmacology; D014158:Transcription, Genetic / Q000187:drug effects / Q000276:immunology; D014407:Tumor Cells, Cultured
chemical_list: C515453:CCL8 protein, human; D018932:Chemokine CCL2; D054412:Chemokine CCL8; D007375:Interleukin-1; D015850:Interleukin-6; D018945:Monocyte Chemoattractant Proteins; D012333:RNA, Messenger; D011994:Recombinant Proteins; D016899:Interferon-beta; D007371:Interferon-gamma